Evidence map›Paper›PMID 41394962›Full record

ArticleMedComm2025

A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer.

Yalun Li, Jin Zhou, Li Jiang, Hua Xie, Zonglian Gong, Ke Wang, Yan Zhang, Yan Li, Weimin Li, Panwen Tian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yalun LiDepartment of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University Chengdu China.
Jin ZhouDepartment of Medical Oncology Sichuan Clinical Research Center for Cancer Sichuan Cancer Hospital & Institute Sichuan Cancer Center Affiliated Cancer Hospital of University of Electronic Science and Technology Chengdu China.
Li JiangDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of North Sichuan Medical College Nanchong China.
Hua XieDepartment of Medical Oncology Sichuan Clinical Research Center for Cancer Sichuan Cancer Hospital & Institute Sichuan Cancer Center Affiliated Cancer Hospital of University of Electronic Science and Technology Chengdu China.
Zonglian GongDepartment of Pulmonary and Critical Care Medicine Affiliated Hospital of North Sichuan Medical College Nanchong China.
Ke WangDepartment of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University Chengdu China.
Yan ZhangLung Cancer Center/Lung Cancer Institute West China Hospital Sichuan University Chengdu China.
Yan LiLung Cancer Center/Lung Cancer Institute West China Hospital Sichuan University Chengdu China.
Weimin LiDepartment of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University Chengdu China.
Panwen TianDepartment of Pulmonary and Critical Care Medicine State Key Laboratory of Respiratory Health and Multimorbidity Precision Medicine Key Laboratory of Sichuan Province West China Hospital Sichuan University Chengdu China.ORCID https://orcid.org/0000-0002-6313-3228

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this Phase II study, 13 patients with stage IIIB/IV non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors were treated with tislelizumab, sitravatinib, and docetaxel. The efficacy and safety were evaluated. The combination treatment achieved median progression-free survival of 7.6 months, median overall survival of 17.2 months, an objective response rate of 58.3% (1 not evaluable), and a disease control rate of 100%. Grade ≥ 3 treatment-related adverse events were primarily neutropenia and leukopenia. Exploratory analyses showed a trend toward increased T cell receptor (TCR) diversity following treatment. High pre-treatment CD8

Indexed as

acquired resistanceCD4+ T cellimmunotherapysingle‐cell secretome proteomicsTCR sequencing

Identifiers

PMID41394962
PMCPMC12696423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.